Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis

Abstract

Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection.

Besifloxacin in the management of bacterial infections of the ocular surface

“…In a rabbit model of keratitis, besifloxacin was significantly more effective than gatifloxacin and moxifloxacin in reducing MRSA colony-forming units. 60,61 Similar results were obtained when besifloxacin was used to treat keratitis induced by P. aeruginosa. 62 In humans, a gradually tapered regimen including besifloxacin was effective in the treatment of a patient with corneal ulcer, presumably because of P. aeruginosa infection.…”

Efficacy of Daptomycin on Experimental Methicillin-Resistant Staphylococcus aureus Keratitis in Rabbits

“…Methicillin-resistant Staphylococcus aureus (MRSA) is increasingly being isolated in cases of bacterial keratitis, in which fortified vancomycin (VA), a glycopeptide antimicrobial, is the current standard of care. 3 However, VA is not stable in an aqueous solution. 2 Moreover, topical VA formulations prepared using saline were reported to irritate the eye due to their low pH, leading to noncompliance.…”

“…1 S. aureus is also the most common causative microorganism in eye infections, causing keratitis, dacryocystitis, and conjunctivitis. [2][3][4] Due to the limited therapeutic options available, methicillin resistance is a significant problem in S. aureus isolates. Methicillin-resistant Staphylococcus aureus (MRSA) is increasingly being isolated in cases of bacterial keratitis, in which fortified vancomycin (VA), a glycopeptide antimicrobial, is the current standard of care.…”

Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections

“…23 Because besifloxacin is new, there are limited experimental or clinical data available to support its in vivo effectiveness, especially within the anterior chamber. [24][25][26][27] The present study was designed to compare the prophylactic effectiveness of moxifloxacin and besifloxacin for experimental methicillin-susceptible S aureus (MSSA) or MRSA rabbit anterior chamber infection.…”